Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elias H Sarkis

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Journal of Attention Disorders|July 13, 2005
Self-regulation and inhibition in comorbid ADHD children: an evaluation of executive functionsStephanie Moulton Sarkis, Elias H Sarkis, David Marshall, et al.
CNS Neuroscience & Therapeutics|February 29, 2016
Atomoxetine Increased Effect over Time in Adults with Attention-Deficit/Hyperactivity Disorder Treated for up to 6 Months: Pooled Analysis of Two Double-Blind, Placebo-Controlled, Randomized TrialsLinda A Wietecha, David B Clemow, Andrew S Buchanan, et al.
The Journal of Clinical Psychiatry|August 24, 2021
A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of AR19, a Manipulation-Resistant Formulation of Amphetamine Sulfate, in Adults With Attention-Deficit/Hyperactivity DisorderStephen V Faraone, Ann Childress, Steve Caras, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|August 23, 2005
Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptomsChristopher J Kratochvil, Jeffrey H Newcorn, L Eugene Arnold, et al.
Future Virology|December 11, 2023
Resistance analysis following sotrovimab treatment in participants with COVID-19 during the phase III COMET-ICE studySambhavi Subramanian, Gretja Schnell, Julia di Iulio, et al.
Journal of Clinical Psychopharmacology|January 2, 2013
Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trialTodd M Durell, Lenard A Adler, Dave W Williams, et al.
Journal of Child and Adolescent Psychopharmacology|October 17, 2017
A 6-Month Open-Label Extension Study of Vortioxetine in Pediatric Patients with Depressive or Anxiety DisordersRobert L Findling, Adelaide S Robb, Melissa P DelBello, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|August 7, 2002
GW320659 for the treatment of attention-deficit/hyperactivity disorder in childrenJoseph DeVeaugh-Geiss, C Keith Conners, Elias H Sarkis, et al.
Expert Review of Neurotherapeutics|October 22, 2015
Atomoxetine monotherapy compared with combination therapy for the treatment of ADHD: a retrospective chart review studyDavid B Clemow, Oren W Mason, Elias H Sarkis, et al.
Journal of Patient-Reported Outcomes|September 13, 2023
Assessment of symptoms in COMET-ICE, a phase 2/3 study of sotrovimab for early treatment of non-hospitalized patients with COVID-19Sacha Satram, Parima Ghafoori, Carolina M Reyes, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Journal of Attention Disorders|July 13, 2005
Self-regulation and inhibition in comorbid ADHD children: an evaluation of executive functionsStephanie Moulton Sarkis, Elias H Sarkis, David Marshall, et al.
CNS Neuroscience & Therapeutics|February 29, 2016
Atomoxetine Increased Effect over Time in Adults with Attention-Deficit/Hyperactivity Disorder Treated for up to 6 Months: Pooled Analysis of Two Double-Blind, Placebo-Controlled, Randomized TrialsLinda A Wietecha, David B Clemow, Andrew S Buchanan, et al.
The Journal of Clinical Psychiatry|August 24, 2021
A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of AR19, a Manipulation-Resistant Formulation of Amphetamine Sulfate, in Adults With Attention-Deficit/Hyperactivity DisorderStephen V Faraone, Ann Childress, Steve Caras, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|August 23, 2005
Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptomsChristopher J Kratochvil, Jeffrey H Newcorn, L Eugene Arnold, et al.
Future Virology|December 11, 2023
Resistance analysis following sotrovimab treatment in participants with COVID-19 during the phase III COMET-ICE studySambhavi Subramanian, Gretja Schnell, Julia di Iulio, et al.
Journal of Clinical Psychopharmacology|January 2, 2013
Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trialTodd M Durell, Lenard A Adler, Dave W Williams, et al.
Journal of Child and Adolescent Psychopharmacology|October 17, 2017
A 6-Month Open-Label Extension Study of Vortioxetine in Pediatric Patients with Depressive or Anxiety DisordersRobert L Findling, Adelaide S Robb, Melissa P DelBello, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|August 7, 2002
GW320659 for the treatment of attention-deficit/hyperactivity disorder in childrenJoseph DeVeaugh-Geiss, C Keith Conners, Elias H Sarkis, et al.
Expert Review of Neurotherapeutics|October 22, 2015
Atomoxetine monotherapy compared with combination therapy for the treatment of ADHD: a retrospective chart review studyDavid B Clemow, Oren W Mason, Elias H Sarkis, et al.
Journal of Patient-Reported Outcomes|September 13, 2023
Assessment of symptoms in COMET-ICE, a phase 2/3 study of sotrovimab for early treatment of non-hospitalized patients with COVID-19Sacha Satram, Parima Ghafoori, Carolina M Reyes, et al.
Pageof 1